Related Experiment Video
Updated: Sep 16, 2025
06:18
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
12.3K
Adenosine improves postmenopausal obesity by regulating neutrophil extracellular traps
Anzhu Wang1, Wei Zhang2, Mengjiao Kang3
1National Center for Integrative Medicine, China-Japan Friendship Hospital, Beijing, 100029, China.
Scientific Reports
|July 9, 2025
Summary
Postmenopausal obesity is linked to inflammation and neutrophil extracellular traps (NETs). Adenosine treatment reduced obesity markers and NETs in a mouse model, suggesting a potential therapeutic strategy.
Area of Science:
- Reproductive Biology
- Immunology
- Metabolic Disorders
Background:
- Postmenopause is associated with altered fat distribution and obesity.
- Obesity is linked to chronic low-grade inflammation.
- Neutrophil extracellular traps (NETs) play a role in inflammation and obesity.
Purpose of the Study:
- To investigate the role of differentially expressed genes (DEGs) in postmenopausal obesity.
- To explore the therapeutic potential of adenosine in mitigating obesity.
- To understand the impact of adenosine on NETs and inflammation in obesity.
Main Methods:
- Identification of DEGs from the GEO database (GSE44000).
- Protein-protein interaction (PPI) network construction and functional enrichment analysis.
- Immune infiltration analysis and in vivo studies using an ovariectomized (OVX) mouse model.
- Assessment of gene expression and NETs markers via RT-qPCR and Western blot.
Main Results:
- 510 DEGs were identified, with 469 upregulated genes associated with inflammation and immune infiltration.
- PPI analysis revealed key genes involved in NETs formation.
- Adenosine treatment in OVX mice decreased body weight, fat, and liver lipids.
- Adenosine reduced NETs markers (ELANE, MPO) and downregulated TNF, ITGB2, and ITGAM.
Conclusions:
- Adenosine ameliorates postmenopausal obesity by regulating NETs markers.
- Inflammation is critical in obesity pathogenesis.
- Adenosine presents a potential novel therapeutic approach for postmenopausal obesity.
Related Concept Videos
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K
01:26Adrenergic Receptors: β Subtype
2.3K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
2.3K
01:31Adrenergic Receptors: ɑ Subtype
2.0K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.0K
01:33Hormonal Regulation
33.7K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
33.7K
01:22Hormonal Regulation of the Menstrual Cycle
713
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
713
01:26Atherosclerosis III: Management
41
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
41